A nti-tumor necrosis factor alpha (TNFa) therapy is frequently used in the treatment of refractory pediatric and adult Crohn's disease (CD). 1 Unfortunately, primary or secondary treatment failure of anti-TNFa treatment is not uncommon. 2 Treatment failure may occur as a result of adverse drug reactions at the time of infusion, lack of primary response to anti-TNFa therapy (primary nonresponse), or diminished response/loss of response to anti-TNFa therapy (secondary loss of response). Primary nonresponse occurs in approximately 13% to 40% of patients, 3, 4 whereas secondary loss of response is estimated to occur at a rate of 8% to 13% per year in infliximab-treated patients and at a similar rate in adalimumab-treated patients. 5, 6 Comparable results were reported from pediatric studies. [7] [8] [9] [10] There are pharmacokinetic (PK), pharmacodynamic, and immunogenic factors that contribute to anti-TNFa treatment failure. 11 PK failure results in decreased drug levels with typically absent or low anti-TNFa antibodies. Immunogenic failure is defined by treatment failure in the setting of low anti-TNFa levels with high levels of antidrug antibodies (ADAs). Pharmacodynamic failure is characterized by either a lack of improvement of CD symptoms or loss of response after initial improvement in the setting of adequate serum drug levels without ADAs. Pharmacodynamic failure is believed to result from a shift in disease course to a non-TNFa-driven pathway. 11 An alternative explanation is that high tissue inflammatory burden in a defined intestinal segment alters drug's efficacy because of increased local concentration of TNFa in severely inflamed tissue combined with localized tissue hypoxia. In the recent ATLAS study, 12 anti-TNFa drug concentration in tissue correlated with degree of endoscopic inflammation, except for tissue with severe inflammation in which anti-TNFa levels were lower suggesting that local tissue inflammation characterized by high levels of TNFa serves as a sink for anti-TNFa, thus tissue levels of anti-TNFa are insufficient to neutralize local TNFa production. Loss of response might result in either a switch to another biologic agent or surgical resection of the refractory inflamed segment. However, surgery rarely results in treatment-free long-term remission, and most patients will develop endoscopic and clinical recurrence on follow-up evaluation. 13 It is not clear whether patients who underwent intestinal resection after anti-TNFa pharmacodynamics failure would benefit from reinstitution of anti-TNFa therapy for postoperative recurrence. Should such benefit be demonstrated it would support the theory that tissue-specific inflammatory burden or poor penetration of the anti-TNFa is the likely cause of anti-TNFa treatment failure rather than a "non-TNFa" pathway.
To test this hypothesis, we aimed to assess the efficacy of postoperative anti-TNFa treatment in children with CD following anti-TNFa pharmacodynamics failure compared with children with different preoperative therapeutic characteristics in a multicenter retrospective study.
MATERIALS AND METHODS

Patients
We conducted a retrospective multicenter cohort study from centers in Europe (the Czech Republic, Finland, the Netherlands, Poland, Belgium, Italy) and Israel. The study cohort included pediatric patients with CD (6-18 years) who underwent intestinal resection and were treated with anti-TNFa agents postoperatively. Patients who received preoperative anti-TNFa treatment were included only if preoperative PK data (drug levels and ADAs) were available. Patients were divided into 2 main groups: (1) Patients who underwent surgical resection because of refractory inflammatory disease following anti-TNFa pharmacodynamic failure and were re-treated with the same anti-TNFa agent for postoperative recurrence. (2) Patients who underwent surgical resection because of refractory disease (including complicated disease) who did not receive anti-TNFa treatment before surgery and were also treated with an anti-TNFa agent for postoperative disease recurrence. Pharmacodynamic failure was defined by refractory disease with either primary failure or secondary loss of response to treatment despite therapeutic serum drug levels ($3 mgr/mL for infliximab and $ 5 mgr/mL for adalimumab without ADAs). Patients with diagnosis of IBD unclassified were excluded.
Description of Variables
The efficacy of postoperative anti-TNFa treatment was determined according to clinical indices and laboratory parameters at 3 different time points: 14 weeks and 1 year after initiation of postoperative anti-TNFa treatment and at the end of follow-up. Preoperative and postoperative demographic, clinical, laboratory (including fecal calprotectin), anthropometric, endoscopic, and anti-TNFa PK data were collected to assess predictors for postoperative anti-TNF treatment efficacy. Clinical indices included Physician Global Assessment (PGA, 0-3; 0-quiescent, 1-mild, 2-moderate, 3-severe) and Pediatric CD Activity Index. Pediatric CD Activity Index data were available for 47 patients (89%) and calprotectin measurements were available for 28 patients (53%). Disease phenotype at diagnosis was categorized according to the Paris classification. 14 Height, weight, and body mass index were converted to age-and sex-adjusted standard deviation scores (Z scores), using the World Health Organization standards. Main outcome measures were defined as clinical remission (according to PGA) at 1 year on anti-TNFa and the proportion of patients still treated with anti-TNFa at the end of follow-up. Secondary outcome measures included mucosal healing during the first year of postoperative anti-TNFa treatment as well as laboratory, anthropometric, and pharmacologic measures at the same time points.
Data Analysis
Continuous variables were evaluated for normal distribution using histogram, Q-Q Plots and Kolmogorov-Smirnov test and reported as median (interquartile range, IQR) for nonnormally distributed variables or mean (standard deviation, SD) for normally distributed variables. Categorical variables were reported as frequency and percentage. Continuous variables were compared using independent simple T test or Mann-Whitney, whereas categorical variables were compared using chi-square test or fisher-exact test. Correlation between continuous variables was evaluated using Spearman rho correlation coefficient.
To strengthen the comparison between groups, patients with pharmacodynamic failure were matched to controls in a ratio of 1:2 (matched case-control). Patients were matched for sex, age, PGA, disease location, and concomitant use of immunomodulator. Continuous variables were compared between matched patients using paired sample T test or Wilcoxon test whereas categorical variables were compared using McNemar test. P , 0.05 was considered as statistically significant. SPSS version 23 (Armonk, NY, IBM Corp) was used for all statistical analyses. The study protocol was approved by the local internal review board at each participating center.
RESULTS
A total of 53 children with CD who underwent intestinal resection and were treated postoperatively with anti-TNFa were included. Median age at diagnosis was 12.6 years (Interquartile range, IQR, 10.8-13.9). Twenty-three were girls (43%) and 49 were white (92%). Median age at surgical resection was 14.8 years (IQR, 13.6-16.5). Distribution of disease location at diagnosis was ileal for 21 patients (40%), colonic for 7 patients (13%), and ileocolonic for 25 patients (47%). Fifty patients (94%) were treated with an immunomodulator preoperatively. Surgical procedures included ileocecal resection for 40 patients (76%), ileocolonic resection for 8 patients (15%), and other procedures including colectomy, hemicolectomy, and isolated ileal resection for 5 patients (9%). Baseline characteristics of the entire cohort are detailed in Table 1 .
The pharmacodynamic failure group comprised 18 patients who were treated preoperatively with anti-TNFa agents (Infliximab, 14 [78%], Adalimumab, 2 [11%], both 2 [11%]), and had adequate drug levels ($3 mgr/mL for Infliximab and $ 5 mgr/mL for Adalimumab) with negative ADAs. The control group comprised 35 patients, 33 of whom were operated because of disease complications (stenotic disease n ¼ 27 [82%], penetrating disease n ¼ 6 [18%] with no preoperative anti-TNFa exposure) and 2 patients who were operated for short inflamed segment with no prior anti-TNFa exposure.
The median time from intestinal resection to anti-TNFa initiation was 8 months (IQR, 4-14 months) with no significant difference between groups. All patients from the pharmacodynamic failure group were treated with the same anti-TNFa agent given before surgery. The indication for postoperative anti-TNFa treatment was disease's exacerbation in all patients. Fifty patients overall (94%) were treated with a combination of an immunomodulator with no significant difference in immunomodulator use among the 2 groups. No significant differences in study variables were recorded when comparing adalimumab treatment versus infliximab treatment or combo versus monotherapy.
At 12 months after postoperative anti-TNFa initiation, 47 patients (89%) were in clinical remission (according to PGA) on anti-TNFa treatment whereas 2 patients experienced primary nonresponse and 4 secondary loss of response (Pharmacodynamic failure group-2 [11%], control group-4 [11.5%], P ¼ 0.9). All patients who experienced secondary loss of response had positive ADAs. Eight patients (15%) required treatment escalation during the first year of postoperative anti-TNFa treatment with no differences between groups. Thirty-one patients (58%) underwent PK studies during the first year of postoperative anti-TNFa treatment with 27 (87%) having adequate drug levels and negative ADAs (no significant difference between the 2 groups). Clinical, laboratory, and anthropometric variables of the 2 groups during the first year of postoperative anti-TNFa initiation are depicted in Table 2 . No significant difference was observed between groups at initiation of postoperative anti-TNFa, 14 weeks and 12 months of treatment. Fecal calprotectin levels were available for 28 (53%) patients (10 in the pharmacodynamic failure group and 18 in controls). At 12 months, 21 patients (75%) had calprotectin level below 200 mgr/gr with no difference between groups (8/10, 80% versus 13/18, 72% in the pharmacodynamic failure group and control group, respectively). Thirty-two patients (60%) underwent a re-evaluation colonoscopy at a median time of 9 months (range: 6-12 months) after postoperative anti-TNFa initiation. Mucosal healing (no inflammatory lesions in all examined intestinal segments including anastomotic site) was observed in 15 patients (47%) and did not differ between groups (6/12, 50% for pharmacodynamic failure and 9/ 20, 45% for controls; P ¼ 0.7).
The median time from postoperative anti-TNFa initiation and end of follow-up was 1.8 years (IQR, 1.0-2.9 years). At that time point, 43 patients were on anti-TNFa treatment (81%), 15 from the pharmacodynamic failure group (83%), and 28 from the control group (80%), P ¼ 0.8 ( Fig. 1) .
For the entire cohort, most of clinical, laboratory, and anthropometric measures improved significantly (P , 0.05 for all variables) from the time of postoperative anti-TNFa initiation to 12 months of treatment with no apparent difference between the 2 groups (Table 3) .
Matched Case-Control Analysis
Matching for age, sex, PGA, disease location, and concomitant use of immunomodulator yielded 14 patients in pharmacodynamic failure group and 28 patients in the control group. At the time of postoperative anti-TNFa initiation there were no differences in clinical, laboratory, and anthropometric measures between groups. Similar proportions of patients from both groups were in clinical remission (according to PGA) on anti-TNFa treatment after 12 months and at the end of follow-up (12/14, 86% versus 25/28, 89% and 11/14, 79% versus. 23/28, 82% for pharmacodynamic failure patients and controls, respectively; P ¼ 0.85). No significant differences were observed at 14 weeks and 12 months of postoperative anti-TNFa treatment in all parameters including endoscopic remission rate and fecal calprotectin.
DISCUSSION
In this study, we demonstrate that pediatric patients with CD who failed anti-TNFa despite adequate therapeutic drug levels can be effectively treated with the same anti-TNFa agent after resection of the severely inflamed intestinal segment. These findings may support the theory that the extreme burden of tissue TNFa within severely inflamed tissue results in failure of anti-TNFa antibodies to neutralize local TNFa production. 12 This process might also be augmented by localized tissue hypoxia in these highly inflamed regions which might further limit anti-TNFa ability to reach the area of most need.
Of the 3 causes of nonresponse or loss of response to antiTNFa medications, pharmacodynamic failure (active disease despite adequate drug levels) is the most intriguing and frustrating one. Whereas PK failure (low drug levels) can be tackled with dose augmentation (either higher dose or shorter dose interval) or possibly the addition of immunomodulator, and immunogenic failure often allows successful reinduction with another antiTNFa agent, pharmacodynamic failure frequently results in low-response rates to a subsequent reinduction with another anti-TNFa 15 with a consequent necessity for changing treatment to a drug with a different mechanism of action. The mechanism which underlies this specific type of treatment failure has long been a matter of debate. A recent study has shown that response to anti-TNFa therapy is associated with the number of TNFaexpressing cells in the mucosa. 16 In a sentinel study, Yarur et al 12 demonstrated that in moderate-to-severely inflamed tissue from adult patients with IBD, the anti-TNFa to TNFa ratio was lower implying that there was insufficient drug to neutralize TNFa. Moreover, severely inflamed tissue had a lower drug level compared with samples with mild-to-moderate inflammation resulting in high serum-to-tissue anti-TNFa ratio. A plausible explanation for this finding is that in severely inflamed tissue with high inflammatory burden, local high levels of TNFa serves as a sink for anti-TNFa antibodies and that tissue injury and local hypoxia might further limit drug penetrance to its target.
If this is indeed the mechanism underlying pharmacodynamic failure, these patients might require a further increase in anti-TNFa dose, way beyond current treatment algorithms. Such a strategy may not be feasible and may be further limited by the lack of safety data supporting higher drug doses and high cost. A valid option for this scenario is to switch treatment out of class but it was shown that refractory anti-TNFa patients are somewhat less likely to respond to other biologics. [17] [18] [19] Perhaps, tissue injury and relative hypoxia limit drug delivery of any sort. In this case, intestinal resection of the severely inflamed segment may restore efficacy of "traditional" biologic therapy such as anti-TNFa agents. The fact that most of the patients in our study who experienced pharmacodynamic failure and underwent a consequent intestinal resection responded postoperatively to the same "failed" anti-TNFa agent lends strong support to the above theory. At 1 year after reinitiation of treatment and at a median follow-up of 1.8 years, this group of patients had comparable response to patients who were naive to anti-TNFa at postoperative treatment initiation. Limited disease, refractory to medical treatment is a known acceptable indication for intestinal resection. 20 However, both clinical and endoscopic recurrence after intestinal resection are common. 21 Pediatric cohort studies reported almost an inevitable postoperative recurrence during long-term follow-up. 22, 23 Postoperative therapeutic strategy in CD was recently revisited. Emerging data from recent trials suggest that prophylactic anti-TNFa may be a highly effective strategy compared with other approaches. 24 A recent randomized controlled trial demonstrated the efficacy of infliximab prophylaxis in preventing endoscopic (though not clinical) postoperative recurrence with an absolute risk reduction of 29%. 25 Specifically, treatment according to clinical risk of recurrence, with early colonoscopy and treatment step-up for recurrence was demonstrated to perform better than conventional drug therapy alone. 26 Surprisingly, only limited data exist regarding treatment for postoperative recurrence, 27 thus, the efficacy of anti-TNFa agents on postoperative recurrence is not well characterized both is adults and in children. In this study, we demonstrated that anti-TNFa treatment for postoperative recurrence in children with CD is highly effective regardless of surgical indication and preoperative treatment. Overall, at 1 year after postoperative anti-TNFa initiation, approximately 88% were in clinical and biochemical remission. When calprotectin was measured, 75% of patients had levels below 200 mgr/gr, and approximately 50% of patients who underwent a follow-up endoscopy had complete mucosal healing. This proportion is comparable to 2 previous reports in adult postoperative patients with CD treated with infliximab for disease recurrence. 28, 29 Response rates in our study are also comparable to those reported in both adult and pediatric patients with CD receiving anti-TNFa agents during early disease course. 1, 9, 10 Despite our novel findings shedding more light on a controversial topic, this study has several limitations. First, the retrospective nature of the study limited complete data collection, including Pediatric CD Activity Index, calprotectin, and endoscopic severity indices. Also, the number of children in this cohort is relatively small, and therefore findings may be at risk of type II error.
In conclusion, we demonstrated that pediatric patients with CD who failed anti-TNFa therapy despite adequate serum drug levels and underwent intestinal resection can be re-treated with the same agent for postoperative recurrence with success rate similar to anti-TNFa naive patients. These findings may support an early surgical approach in patients with limited disease, refractory to anti-TNFa treatment.
